Annual report pursuant to Section 13 and 15(d)

Loans Receivable (Tables)

v3.22.4
Loans Receivable (Tables)
12 Months Ended
Dec. 31, 2022
Loans Receivable  
Schedules of loans receivables

A breakdown of the loans receivable terms and balances are as follows:

Loans receivable

    

December 31, 2022

    

December 31, 2021

Teneo Fund SPVi LLC Note

$

5,911

$

5,911

Pharma EU, LLC Note

1,410

1,410

A&R Note

710

714

SSZ and Elev8 Note

1,002

1,002

Pure Hana Synergy Note

224

224

Little Beach Harvest Note

2,199

423

Total loans receivable

$

11,456

$

9,684

Less allowance for expected credit losses

(7,237)

(5,559)

Loans receivable, net of expected credit losses

4,219

4,125

Less current portion of loan receivable

(516)

(2,453)

Loans receivable, long-term

$

3,703

$

1,672

Schedule of analysis of credit quality of loans receivable

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime current expected credit loss (“CECL”) reserves:

As of December 31, 2022

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

9,822

$

(5,915)

$

3,907

Third party guarantee

1,410

(1,098)

312

No collateral

224

(224)

Net loans receivable

$

11,456

$

(7,237)

$

4,219

As of December 31, 2021

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

8,050

$

(4,556)

$

3,494

Third party guarantee

1,410

(882)

528

No collateral

224

(121)

103

Net loans receivable

$

9,684

$

(5,559)

$

4,125